Here are five things to know:
1. Invibio is redefining total cost of care by focusing on clinical outcomes and studies instead of total upfront costs. The company knows the medical device industry faces difficulty conducting clinical studies while trying to keep costs low.
2. Recently, the company hired a clinical study manager to work with healthcare professionals, medical device manufacturers and stakeholders. Invibio hired a clinical relations expert to interact with healthcare professionals, hospitals and payers.
3. Investments in component manufacturing and testing are designed to simplify the process for medical device companies to innovate and change a product’s development or add product lines.
4. Along with its investments, Invibio launched a new comprehensive annual journal Invibio Insider, which offers insights into understanding clinical evidence and outcomes. It also investigates approaches for treating complex cases.
5. Invibio plans to use its website as a center for original equipment manufacturers and healthcare professionals to obtain education resources for Peek-Optima and facilitate clinical adoption of new medical devices.
More articles on devices and implants:
1st Titan Spine Endoskeleton cases performed in Australia: 4 insights
5 opportunities, forecasts in global orthopedic implants market
OrthoPediatrics amends distribution agreement with Bioretec: 5 things to know
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
